Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Whipple disease and tropical malabsorption

Gastroenterology and hepatology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull

Synopsis

Recognise Whipple disease and travel-related malabsorption without collapsing them into a single tropical diagnosis, select tissue, molecular and stool tests with microbiology, and begin prolonged organism-specific therapy only with infection and gastroenterology expertise using current reference-laboratory, UKHSA, BNF and local imported-infection guidance.

  • Classic Whipple disease is caused by Tropheryma whipplei and often presents with years of migratory seronegative arthralgia before weight loss, diarrhoea, abdominal pain, nodes or systemic disease.
  • Neurological, ocular and culture-negative endocarditis presentations can occur without obvious diarrhoea; cognitive change, supranuclear gaze disorder or oculomasticatory movements are high-risk clues.
  • Duodenal histology with PAS-positive macrophages plus organism-specific PCR on appropriately chosen samples supports diagnosis; stool or saliva PCR alone can reflect carriage.
  • Exclude Whipple disease before escalating immunosuppression in a credible multisystem inflammatory mimic because corticosteroids or biologics can accelerate infection.
  • Tropical malabsorption is a syndrome, not an aetiology: travel geography, duration, food and water, freshwater, barefoot soil, medicines, immune state and onset guide testing.
  • Giardia, Strongyloides, HIV-related infection, intestinal tuberculosis, coeliac disease and pancreatic disease are generally more defensible targets than assuming tropical sprue.
  • UK SMI guidance supports Giardia and Cryptosporidium in primary testing for symptomatic diarrhoea, with travel- and immune-specific parasite investigations added explicitly.
  • Treat severe dehydration, electrolyte depletion, malnutrition and refeeding risk immediately while diagnostic sampling continues.

Key red flags

Neurological Whipple disease

Cognitive or behavioural change, ataxia, hypothalamic features, supranuclear gaze palsy, myoclonus or oculomasticatory movements requires urgent CNS-aware diagnostic and treatment planning.

Culture-negative endocarditis

Valvular infection, embolic phenomena or heart failure with negative routine cultures can be T. whipplei even without gut symptoms; valve tissue PCR may be decisive.

Severe nutritional syndrome

Dehydration, oedema, profound anaemia, tetany, arrhythmia or neurological deficiency requires admission and cautious nutrition support while cause-specific tests proceed.

Investigation priorities

01
Upper endoscopy with duodenal histologyFirst step

Obtain multiple proximal and distal duodenal biopsies for PAS staining and pathology when classic Whipple or another enteropathy is suspected.

Management branches

WhippleMultisystem diagnostic pathway

Arthralgia plus malabsorption, neurological disease or culture-negative endocarditis makes T. whipplei plausible.

  1. Stop diagnostic anchoring, review prior immunosuppression and involve gastroenterology, infection or microbiology and the organ-specific team.
  2. Obtain duodenal histology and reference PCR from the most informative compartments before antibiotics when safe, without delaying treatment for unstable CNS or cardiac disease.
  3. Confirm concordance and exclude PAS or PCR mimics before committing to prolonged therapy.
  4. Plan a CNS-penetrating induction and prolonged eradication regimen with relapse surveillance through specialists.

Key medicines

Whipple disease antimicrobial regimenSpecialist induction with a CNS-penetrating intravenous agent followed by prolonged oral eradication therapy, chosen through infection and microbiology guidance; verify current BNF and reference advice.Regimen and duration are not safely standardised from a summary. Check CNS involvement, interactions, cytopenia, renal or hepatic toxicity and late relapse; avoid brief empirical courses.
Metronidazole or tinidazole for giardiasisUse the current BNF organism-specific adult regimen after laboratory or strongly supported imported-infection diagnosis.Alcohol advice, gastrointestinal effects, neuropathy with prolonged metronidazole and interactions matter. Reassess household or reinfection exposure and persistent symptoms.
Open full textbook →Answer 2 questions
Sources and review status5 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • RCPath UK SMI ID10: Aerobic actinomycetesCurrent UK laboratory context for Tropheryma whipplei identification.
  • RCPath UK SMI S7: GastroenteritisCurrent 2026 travel, immune and parasite testing pathway.
  • BSG chronic diarrhoea guidelineMalabsorption, infection and small-bowel investigation.
  • BNF: Antibacterial drugsCurrent UK treatment safety and interaction context.
  • NICE CG32: Nutrition supportSevere malnutrition and refeeding prevention.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom